8-K current report · filed Oct 9, 2026

Vaxcyte, Inc. (PCVX) 8-K Current Report: October 9, 2026

Item 1.01Item 2.03Item 8.01PCVX overview

Short answer

Vaxcyte, Inc. (PCVX) filed an 8-K current report with the SEC on October 9, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 8.01 (Other Events). $575M raised through 1.50% convertible senior notes due October 2032, strengthening funding capacity at low cash interest cost.

Vaxcyte, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $575M raised through 1.50% convertible senior notes due October 2032, strengthening funding capacity at low cash interest cost
  • Semiannual interest payments begin April 15, 2027, creating a long-dated fixed financing obligation
  • Initial conversion price approximately $89.60 per share, potentially diluting shareholders if Vaxcyte’s stock appreciates
  • Redemption permitted from October 22, 2029 if shares exceed 130% of the conversion price across specified trading periods
  • Fundamental-change and delisting provisions give noteholders repayment rights, potentially increasing transaction-related financing constraints

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 points investors to Item 1.01 for details of any direct financial obligation
  • Financial impact depends on the referenced agreement’s payment terms, commitments and timing

Item 8.01 · Other Events

  • Concurrent offerings closed October 9, 2026, raising approximately $1.103 billion net for Vaxcyte
  • Equity financing included 8,584,375 shares after full option exercise, creating substantial shareholder dilution
  • Equity proceeds approximately $544.3 million, with shares priced at $64.00
  • Convertible debt proceeds approximately $558.7 million, including $575.0 million principal at 1.50% due 2032
  • Pre-funded warrants for 400,000 shares carry a $0.001 exercise price, adding potential future dilution

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Vaxcyte, Inc. 8-K filings

Get the next PCVX 8-K as it lands

Follow PCVX for push alerts, or ask the research agent what this filing means.